STAT

‘Beyond amyloid’: A look at what’s next in Alzheimer’s research

A parade of failed clinical trials has stoked new research efforts, as the field in general and its pharma colleagues think beyond amyloid hypothesis.

It’s neuroscience’s oldest and most acrimonious debate. On one side, scientists who aver that blasting away toxic plaques called amyloid is the best path toward treating Alzheimer’s disease. On the other, frustrated skeptics ready to ditch the amyloid hypothesis once and for all.

But a parade of failed clinical trials has seeded a growing middle ground of agnostics and stoked a bevy of new research efforts, as “the field in general — and our pharma colleagues — are recognizing that they need to think beyond amyloid,” said Dr. David Knopman, a neurologist at the Mayo Clinic.

Here’s a look at some of the most interesting ideas from the beyond.

What about the immune system?

The memory-destroying effects of Alzheimer’s unassailably take place in the brain, but mounting research suggests that the body’s natural defenses, hardly infallible, are unwittingly

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About A Senate Probe Into Novo Pricing, A New UTI Antibiotic, And More
The U.S. Senate health committee is investigating the prices Novo Nordisk charges for its blockbuster medications Ozempic and Wegovy.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About Wegovy And Ozempic Sales, Rising Pharma Layoffs, And More
Sales of the blockbuster Wegovy obesity treatment more than doubled in the first quarter as Novo Nordisk races to make more of the drug to meet surging demand.
STAT2 min readAmerican Government
STAT+: Pharmalittle: We’re Reading About FTC Reviewing Novo-Catalent Deal, Amneal Opioid Settlement, And More
The FTC wants more information on a $16.5 million deal in which Novo Nordisk's parent company would purchase Catalent, a contract drug manufacturer.

Related Books & Audiobooks